Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BQ65

UPID:
USB1_HUMAN

ALTERNATIVE NAMES:
3'-5' RNA exonuclease USB1; Mutated in poikiloderma with neutropenia protein 1

ALTERNATIVE UPACC:
Q9BQ65; B4DWE3; B4DZW5; Q96FZ9; Q9H8X8

BACKGROUND:
The protein U6 snRNA phosphodiesterase 1, known alternatively as 3'-5' RNA exonuclease USB1, is integral to the maturation of U6 snRNA, a component of the spliceosome. By trimming oligo(U) and oligo(A) tracts, it ensures the proper formation of a mature U6 snRNA, crucial for RNA splicing and gene expression regulation.

THERAPEUTIC SIGNIFICANCE:
The association of U6 snRNA phosphodiesterase 1 with Poikiloderma with neutropenia highlights its clinical relevance. This connection underscores the importance of exploring this protein's function further to develop innovative treatments for related genetic disorders. Understanding the role of U6 snRNA phosphodiesterase 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.